Nath Bio Genes India Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Nath Bio Genes India Q2 results FY27 announcement is the next scheduled earnings event for Nath Bio-Genes (India) Ltd., Nath Bio-Genes (India) Ltd develops, produces and sells hybrid seeds for crops such as cotton, maize, rice and vegetables, with sales concentrated around the kharif sowing season.. The stock traded at Rs 146.00 on the NSE on 17 September 2026, down 0.03% from the previous close of Rs 146.05, about 28.4% below its 52-week high of Rs 204.00 and 15.7% above its 52-week low of Rs 126.15.

What makes the Nath Bio Genes India Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 44.00 crore of revenue and a profit of Rs 5.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 328.00 crore and a profit of Rs 32.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Nath Bio Genes India Q2 Results FY27 Date?

The Nath Bio Genes India Q2 results date for FY27 is not confirmed. As of 17 September 2026, Nath Bio-Genes (India) Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Nath Bio Genes India Q2 results date becomes public through that filing rather than through any advance announcement.

Also read – Jio Financial Services Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Nath Bio Genes India Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Nath Bio Genes India.

Nath Bio Genes India Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Nath Bio Genes India Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Nath Bio Genes India. The Nath Bio Genes India Q2 results watchlist below is built from what the company has actually reported and disclosed.

Nath Bio Genes India Q2 results are due as part of the broader Q2 FY27 reporting season, but for this seed company the September quarter is structurally smaller than what a typical Q2 print might suggest. Screener data shows that revenue in the September quarter (44 Cr in Sep25) is only a fraction of the June quarter's 284-328 Cr, since kharif seed dispatches are concentrated between April and June. When Nath Bio Genes India Q2 results for the September 2026 quarter arrive, they should be read as an off-season update on the September 2026 quarter rather than a continuation of the June quarter's scale.

This pattern is consistent with how India's kharif sowing cycle drives hybrid seed sales, concentrating dispatches into the June quarter and leaving September, December and March as smaller, servicing-and-collection quarters, a trend visible in past Nath Bio Genes India Q2 results filings. Operating margin across these smaller quarters has ranged from about 5% in Dec25 to 14% in Sep25, and Mar26 net profit was reported as essentially nil, showing how thin off-season economics can get. None of this points to weakening demand; it is simply the standard cadence of an agri-input seed business.

Given this seasonality, Nath Bio Genes India Q2 results for the September 2026 quarter are unlikely to match the scale of the June 2026 quarter's 328 Cr revenue and 35 Cr operating profit, and that gap is expected rather than a sign of weakness. The more relevant yardstick is the year-ago September quarter, when revenue was 44 Cr, operating profit was 6 Cr and net profit was 5 Cr. Readers following Nath Bio Genes India Q2 results should judge the September 2026 quarter against that prior off-season print rather than against the just-concluded peak season.

Check Nath Bio-Genes (India) Ltd. Live Fundamentals on the Univest Screener

Nath Bio Genes India Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Nath Bio-Genes (India) Ltd. reported revenue of Rs 328.00 crore in Q1 FY27, up 15.49% from Rs 284.00 crore in Q1 FY26, and a profit of Rs 32.00 crore at the net level, up 14.29% from Rs 28.00 crore in Q1 FY26. These are reported actuals, not estimates.

Also read – JK Paper Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Sequentially, revenue was up 530.77% over the March 2026 quarter figure of Rs 52.00 crore, and net profit was a swing from a loss of Rs 0.00 crore in Q4 FY26 to a profit of Rs 32.00 crore. Operating margin stood at 10.0% in Q1 FY27 against 14.0% in the September 2025 quarter, which is the comparison the Nath Bio Genes India Q2 results print will be read against.

Q2 FY26 Base: The Comparison Nath Bio Genes India Q2 Results FY27 Must Beat

Nath Bio-Genes (India) Ltd. reported revenue of Rs 44.00 crore and a profit of Rs 5.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Nath Bio Genes India Q2 results preview.

Net profit in that base quarter was below the Rs 32.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 44.00 crore sits below the Rs 328.00 crore of the June 2026 quarter, which frames how much sequential movement the Nath Bio Genes India Q2 results print needs to show growth.

Nath Bio Genes India Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	44.00	5.00
Q3 FY26 (Dec 2025)	66.00	2.00
Q4 FY26 (Mar 2026)	52.00	0.00
Q1 FY27 (Jun 2026)	328.00	32.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Nath Bio Genes India Q2 results preview uses.

Revenue across those four quarters ranged from Rs 44.00 crore to Rs 328.00 crore, and net profit from Rs 0.00 crore to Rs 32.00 crore. That spread is the honest context for the Nath Bio Genes India Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Nath Bio Genes India Q2 Results FY27

The Nath Bio Genes India Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Nath Bio Genes India has already reported.

Kharif Seasonality Skews Quarterly Comparisons

Nath Bio Genes India Q2 results have historically shown the September quarter running far below the June quarter in both revenue and profit, purely because of the kharif sowing calendar. This is a structural feature of the seed business, not a quarterly red flag, so a sequential comparison against the June quarter would be misleading for this stock.

Thin Off-Season Profitability

Outside the June quarter, operating margins for this business have ranged from roughly 5% to 14%, and Mar26 net profit came in at close to nil on the screener. Such swings show how a modest change in costs or seed realizations can compress profitability once the seasonal revenue base shrinks, a pattern that recurs across Nath Bio Genes India Q2 results and the other off-season quarters.

Valuation and Returns Context

The stock currently trades at a trailing PE of about 8.3x with a return on equity of 5.47%, both shaped by this annual seasonality rather than by any single quarter's print. As Nath Bio Genes India Q2 results for the September 2026 quarter are released, they will add one more data point to that seasonal pattern without altering the underlying seed-sales business model, and comparisons should stay anchored to the year-ago Nath Bio Genes India Q2 results rather than the June quarter just gone.

Nath Bio Genes India Q2 Results FY27: Share Price and Valuation Going Into the Print

Nath Bio Genes India share price today is Rs 146.00 on the NSE, down Rs 0.05 or 0.03% from the previous close of Rs 146.05 on 17 September 2026, ahead of the Nath Bio Genes India Q2 results announcement.

Metric	Value (17 September 2026)
NSE Symbol	NATHBIOGEN
Current Market Price	Rs 146.00
52-Week High	Rs 204.00
52-Week Low	Rs 126.15
Market Capitalisation	Rs 277 crore
PE Ratio	8.18
PB Ratio	0.41
EPS (TTM)	Rs 17.85
Book Value per Share	Rs 358.00
Debt to Equity	0.20
Return on Equity	5.47%
50-Day Moving Average	Rs 156.83
200-Day Moving Average	Rs 156.62
RSI (14)	30.21

The stock trades below both its 50-day average of Rs 156.83 and its 200-day average of Rs 156.62, with a 14-day RSI of 30.21. None of this is a view on where the shares go once the Nath Bio Genes India Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Nath Bio-Genes (India) Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Nath Bio Genes India Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Nath Bio Genes India Q2 results print in proportion.

1. Revenue against the Rs 44.00 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 5.00 crore in that same quarter
3. Operating margin against 10.0% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Nath Bio Genes India Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Nath Bio Genes India Q2 Results FY27

The Nath Bio Genes India Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Nath Bio-Genes (India) Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Nath Bio Genes India Q2 results FY27 print faces a base of Rs 44.00 crore in revenue and a profit of Rs 5.00 crore, with the most recent quarter having delivered Rs 328.00 crore and a profit of Rs 32.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Nath Bio Genes India, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Nath Bio Genes India Q2 Results FY27

What is the Nath Bio Genes India Q2 results date for FY27?

Ans. The Nath Bio Genes India Q2 results date for FY27 is not confirmed. Nath Bio-Genes (India) Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Nath Bio Genes India Q2 results 2026 cover?

Ans. The Nath Bio Genes India Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Nath Bio-Genes (India) Ltd. reports revenue, operating profit and net profit for that period, and the Nath Bio Genes India Q2 results filing also carries the notes to the accounts.

What were the Nath Bio Genes India Q1 FY27 results?

Ans. Nath Bio-Genes (India) Ltd. reported revenue of Rs 328.00 crore in Q1 FY27 and a profit of Rs 32.00 crore at the net level. Revenue was up 15.49% versus Q1 FY26 and net profit was up 14.29% from Rs 28.00 crore in Q1 FY26.

What were Nath Bio Genes India Q2 FY26 results in the September 2025 quarter?

Ans. Nath Bio-Genes (India) Ltd. reported revenue of Rs 44.00 crore and a profit of Rs 5.00 crore in Q2 FY26. Operating margin was 14.0%. Those figures form the base for the Nath Bio Genes India Q2 results FY27 comparison.

What are the main Nath Bio Genes India Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Nath Bio Genes India Q2 results expectations centre on revenue against the Rs 44.00 crore base, net profit against a profit of Rs 5.00 crore, operating margin against 10.0% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Nath Bio Genes India share price today ahead of the Q2 earnings?

Ans. Nath Bio Genes India share price is Rs 146.00 on the NSE as of 17 September 2026, down 0.03% from Rs 146.05. The stock is about 28.4% below its 52-week high of Rs 204.00 and 15.7% above its 52-week low of Rs 126.15, at a market capitalisation of Rs 277 crore.

Is Nath Bio Genes India a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Nath Bio-Genes (India) Ltd. The stock trades at a price-to-book ratio of 0.41 with a return on equity of 5.47%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.